Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Hauser

Showing results (171-180 of 419) with videos related to

Pageof 42
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 11, 2023
Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extensionStephen L Hauser, Ronald Zielman, Ayan Das Gupta, et al.
Archives of Neurology|September 1, 1992
An antispasticity effect of threonine in multiple sclerosisS L Hauser, T H Doolittle, M Lopez-Bresnahan, et al.
Journal of Neuroimmunology|October 1, 1983
Immunohistochemical staining of human brain with monoclonal antibodies that identify lymphocytes, monocytes, and the Ia antigenS L Hauser, A K Bhan, F H Gilles, et al.
Annals of Neurology|January 13, 2018
Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout diseaseChristina J Azevedo, Steven Y Cen, Sankalpa Khadka, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2018
Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesionsColm Elliott, Jerry S Wolinsky, Stephen L Hauser, et al.
European Journal of Neurology|March 16, 2021
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trialsGavin Giovannoni, Ludwig Kappos, Jerome de Seze, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 11, 1995
Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitorC P Genain, T Roberts, R L Davis, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|October 2, 2019
Intersubject Variability and Normalization Strategies for Spinal Cord Total Cross-Sectional and Gray Matter AreasNico Papinutto, Carlo Asteggiano, Antje Bischof, et al.
Human Molecular Genetics|December 3, 2005
Association of the truncating splice site mutation in BTNL2 with multiple sclerosis is secondary to HLA-DRB1*15James A Traherne, Lisa F Barcellos, Stephen J Sawcer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 2014
Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patientsArumugam Palanichamy, Sarah Jahn, Dorothee Nickles, et al.
Pageof 42

Showing results (171-180 of 419) with videos related to

Sort By:
Pageof 42
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 11, 2023
Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extensionStephen L Hauser, Ronald Zielman, Ayan Das Gupta, et al.
Archives of Neurology|September 1, 1992
An antispasticity effect of threonine in multiple sclerosisS L Hauser, T H Doolittle, M Lopez-Bresnahan, et al.
Journal of Neuroimmunology|October 1, 1983
Immunohistochemical staining of human brain with monoclonal antibodies that identify lymphocytes, monocytes, and the Ia antigenS L Hauser, A K Bhan, F H Gilles, et al.
Annals of Neurology|January 13, 2018
Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout diseaseChristina J Azevedo, Steven Y Cen, Sankalpa Khadka, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2018
Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesionsColm Elliott, Jerry S Wolinsky, Stephen L Hauser, et al.
European Journal of Neurology|March 16, 2021
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trialsGavin Giovannoni, Ludwig Kappos, Jerome de Seze, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 11, 1995
Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitorC P Genain, T Roberts, R L Davis, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|October 2, 2019
Intersubject Variability and Normalization Strategies for Spinal Cord Total Cross-Sectional and Gray Matter AreasNico Papinutto, Carlo Asteggiano, Antje Bischof, et al.
Human Molecular Genetics|December 3, 2005
Association of the truncating splice site mutation in BTNL2 with multiple sclerosis is secondary to HLA-DRB1*15James A Traherne, Lisa F Barcellos, Stephen J Sawcer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 2014
Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patientsArumugam Palanichamy, Sarah Jahn, Dorothee Nickles, et al.
Pageof 42